NASDAQ: BLLN

BillionToOne (BLLN) Stock Analysis & Forecast

Nov 13 close

$105.15−5.64 (−5.1%)

Gekko Brief

AI summaryNov 9 close

BillionToOne's week centers on third-quarter results, raised guidance, and insider stock sales. The company reported revenue of $122.98 million and net profit of $17.39 million for Q3 2026, surpassing earnings and revenue estimates, and raised its full-year revenue outlook after sales rose 47% from a year earlier, driven by growth in prenatal and oncology testing, marking a fifth consecutive quarter of positive GAAP operating income. Stifel Nicolaus maintained a Buy rating with a $145.00 price target following the report. Separately, CTO David Tsao sold 20,000 shares at an average price of $109.24, and CEO Oguzhan Atay and his spouse sold 30,335 Class A shares at prices ranging from $107.3142 to $113.1700, both following option exercises at $2.80 per share.

BLLN closed at $114.95, up 0.9%, sitting above both its 50-day average of $105.80 and 200-day average of $97.16, with the shorter average above the longer one. The GekkoIndex reads 51.2, placing the stock in the Neutral zone. Price stands 33.3% below Gekko Fair Value of $172.27.

The next earnings date falls on 3 March 2027, outside a typical 20-trading-day window. Over the last 30 days, there has been 1 unusual options signal, with put premium of $782,070 against call premium of $313,250. The consensus among 5 analysts rating the stock a Buy stands at a $129 target, implying 12.2% upside from current levels.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

BillionToOne price vs fair value

$167.90$105.15Nov ’25May ’26Nov ’26
Close $105.15200-day averageGekko Fair Value $167.90

BillionToOne quick facts

Market cap
$5.02B
P/E ratio
120.4
Forward P/E
67.1
EPS, TTM
$0.92
Revenue, TTM
$436.9M
Profit margin
10.5%
Dividend yield
—
Beta
—
Volume
647,690 avg 617,529
1-year return
+3.3%
Typical daily move
±6.1%
Typical 20-day move
±13%
50-day average
$106.99
200-day average
$97.66
Next earnings
Mar 3
Shares outstanding
43.27M
52-week range
$61.96$150.44

BillionToOne swing-trade checklist

BillionToOne scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $105.15 sits between the 50-day ($106.99) and 200-day ($97.66) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    62.2, Accumulation

    Reading 62.2 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    37.4% below

    Price is 37.4% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyheadwind

    Leans bearish

    Last 30 days: 2 unusual options signals.

    See smart money
  • Earnings risksupportive

    Reports in 108 days

    Next report Mar 3, 2027, 108 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityno data

    No data

    Not enough years of history for a seasonal read.

A description of current data, not a recommendation. How this page works

BillionToOne stock chart and price history

BillionToOne closed at $105.15 on Nov 13, 2026, +3.3% over the past year, inside a 52-week range of $61.96 to $150.44.

Close50-day average200-day averageVolume
BillionToOne share price, past year, with 50-day and 200-day moving averages and volume$60$80$120$140DecJan 2026FebMarAprMayJunJulAugSepOctNov105.15

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+2.4%
3 months
+12.0%
6 months
+27.3%
1 year
+3.3%
The full BLLN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BLLN in Gekko

Follow BillionToOne through every session

Put BLLN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BLLN in GekkoFree for 7 days. No credit card required.

About BillionToOne

BillionToOne builds molecular diagnostic tests around a platform that counts single strands of DNA, aiming to sharpen how accurately diseases can be detected. Rather than relying on broader estimates, the company's approach focuses on isolating and tallying individual molecules, which underlies its work in prenatal and cancer testing.

Among its offerings is UNITY Complete, a screening test that uses a blood draw from an expectant mother to gauge a fetus's chances of aneuploidies, recessive genetic disorders, and fetal antigen issues without any invasive procedure. On the oncology side, Northstar Select analyzes a patient's blood to detect tumor-related mutations, including deletions, insertions, and single-point changes, while Northstar Response follows how a cancer evolves over time by examining methylation patterns. These tools are aimed at supporting both expectant parents and cancer patients through ongoing clinical monitoring.

Founded in 2016, BillionToOne runs its operations out of Menlo Park, California. The company trades on the NASDAQ exchange under the ticker symbol BLLN.

Listed
NASDAQ
Sector
Health services
Industry
Medical/Nursing services
Website
billiontoone.com

BillionToOne GekkoIndex: the smart money zone

BillionToOne’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 62.2, in the Accumulation zone, up 10.2 points over five sessions.

010062.2Accumulation

Up 10.2 points over five sessions, from the Neutral zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying12+9.2%+14.4%+5.2%+1.2%
Accumulation (current zone)97+2.9%+4.4%+5.0%+6.4%
Neutral128−1.0%−1.5%−1.0%+6.0%
Distribution10−6.0%−4.5%−2.9%−15.4%
Selling0Not available

Average BLLN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the BLLN price, zone by zone.Track BLLN in Gekko

Is BillionToOne stock overvalued? Gekko Fair Value

BillionToOne trades 37.4% below Gekko Fair Value of $167.90, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what BillionToOne shares are worth, recalculated every trading day.

$167.90

Gekko Fair Value, Nov 14, 2026

37.4% Undervalued

At the end of Sep 2026 the price was 36.5% below the estimate.

Gekko Fair ValueShare price, month end
$168$105Sep 2026OctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BLLN in Gekko

BillionToOne insider and Congress trading

No open-market insider purchases were filed for BillionToOne, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BLLN in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BLLN insider filing, plotted on the chart in Gekko.Open BLLN in Gekko

Congress trades last 90 days

No trades in BLLN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BLLN, plotted on the chart in Gekko.Open BLLN in Gekko

Buybacks

BillionToOne has been buying back its own shares.

Bought back, year ended Dec 31, 2024
$546K
As a share of market cap
0.01%

From company filings.

Unusual options activity last 30 days

2signals, 48% of the flagged premium in calls.

Latest: Bullish flow on Nov 14, $418K in unusual premium.

Every signal with its contract, strike and premium.Unlock in Gekko

BillionToOne earnings: next date and track record

BillionToOne reports on Mar 3, 2027 (108 days away), and beat the EPS estimate in 2 of its last 5 reports.

2 of 5reports beat the EPS estimate
±16.5%average move across the report
1 of 4reports followed by a gain

Share-price move across each report

−0.9%Dec ’25−13.2%Mar ’26+16.3%May ’26−35.6%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
BilliontoOne (BLLN) reported strong Q2 2026 results with test volume up 35% YoY and revenue up 64% YoY, achieving an annualized revenue run rate of $438 million. Gross margins expanded 5 percentage points to 70.5% YoY. The company generated $5.5 million GAAP operating income (5% margin) and 15% adjusted EBITDA margin. Cash position grew to $549 million. New product launches in prenatal (UnityConfirm) and oncology are underway, with MolDX coverage data published for North Star Response.
Guidance
Management is pursuing MolDX reimbursement coverage for North Star Response and scaling new prenatal and oncology product launches. Long-term targets include S&P 500 membership and capturing a share of an estimated $100 billion U.S. cell-free DNA market opportunity.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$0.15
est $0.18
−18.2%$109.4M
est $109.2M
+0.2%−35.6%
May 6, 2026$0.34
est $0.03
+981.8%$108.4M
est $97.14M
+11.6%+16.3%
Mar 4, 2026$0.11
est $0.06
+82.7%$96.05M
est $87.19M
+10.2%−13.2%
Dec 9, 2025$0.10
est $0.14
−28.3%$83.50M
est $82.90M
+0.7%−0.9%
Oct 7, 2025−$0.02
est $0.14
−114.3%$66.60M
est $82.90M
−19.7%—

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

BillionToOne stock forecast and analyst price targets

Analysts’ average 12-month price target for BillionToOne is $128.29, +22.0% from the last close, from 5 firms rating the stock in the last 90 days.

$128.29consensus 12-month target, +22.0% from the last close
Low $120High $145
Buy5
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 5 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Piper SandlerBuy, reiterated$130+23.6%
Nov 5Canaccord GenuityBuy, maintained$120+14.1%
Nov 5J.P. MorganBuy, maintained$135+28.4%
Nov 5Stifel NicolausBuy, maintained$145+37.9%
Nov 5Piper SandlerBuy, reiterated$140+33.1%
+5.0%average 20-day move after past Accumulation readings
±6.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

BillionToOne market cap and key statistics

BillionToOne’s market cap is $5.02B, with a P/E ratio of 120.4 and revenue of $436.9M over the last twelve months.

Valuation

Market cap
$5.02B
P/E ratio
120.4
Forward P/E
67.1
EPS, TTM
$0.92
Gekko Fair Value
$167.90

Trading

Volume
647,690
Avg volume, 20 days
617,529
52-week high
$150.44
52-week low
$61.96
Shares outstanding
43.27M

Financials

Revenue, TTM
$436.9M
Profit margin
10.5%
Return on equity
13.2%
Quarterly earnings growth, YoY
+220.0%

Risk and income

Typical daily move
±6.1%
Typical 20-day move
±13%

BillionToOne peers

BillionToOne’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LHLabcorp−1.0%Neutral8.5% above
GHGuardant Health−2.8%Accumulation16.4% below
SOLVSolventum0.0%Neutral17.0% below
BTSGBrightSpring Health Services0.0%Neutral11.0% above
EHCEncompass Health−0.4%Neutral14.7% above
ENSGEnsign+0.3%Neutral15.6% above

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical/Nursing services

BillionToOne stock FAQ

What is BillionToOne’s market cap?

BillionToOne’s market cap is $5.02B at the Nov 13, 2026 close of $105.15, with 43.27M shares outstanding. The shares trade on a P/E ratio of 120.4.

What is the BillionToOne stock forecast?

The consensus analyst 12-month price target for BillionToOne is $128.29, +22.0% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is BillionToOne stock overvalued or undervalued?

On Gekko’s estimate BillionToOne is undervalued: the Nov 13, 2026 close of $105.15 is 37.4% below Gekko Fair Value of $167.90. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does BillionToOne report earnings next?

BillionToOne is expected to report on Mar 3, 2027 (108 days away). Analysts expect earnings of $0.16 per share on revenue of $122.4M. BillionToOne beat the earnings estimate in 2 of its last 5 reports, moving 16.5% on average across the report.

What is BillionToOne’s 52-week high and low?

BillionToOne’s 52-week high is $150.44 and its 52-week low is $61.96; it closed at $105.15 on Nov 13, 2026, +3.3% over the past year.

Is BillionToOne stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in BillionToOne?

Gekko flagged 2 unusual options signals in BillionToOne over the last 30 days, with $731K of flagged premium in calls and $782K in puts. The latest, bullish flow, was on Nov 14, 2026 with $418K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See BillionToOne the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.